Potential protective effects of antihypertensive treatments during the Covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers

Figures & data

Table 1. Potential protective mechanisms of beta-adrenergic receptor blocker treatment in Covid-19 disease (summarized from ref. [16]).

1. Beta-adrenergic blockers reduce the SARS-COV-2 host cell entry

2. Beta adrenergic blockers reduce interleukin-6 (IL-6)

3. Beta adrenergic blockers decrease pro-inflammatory cytokines and inhibit cytokine storm

4. Beta-adrenergic blockers might be beneficial in acute respiratory distress syndrome (ARDS) and respiratory failure condition

5. Beta-adrenergic blockers are beneficial in septic shock

6. Beta-adrenergic blockers may reduce the pulmonary edoema

7. Beta adrenergic blockers may reduce the hyper-coagulation state and prevent pulmonary embolism in Covid-19 patients

8. Beta-adrenergic blockers may improve oxygenation level

9. Beta-adrenergic blockers may reduce the mucus hypersecretion in Covid-19

10. Computational studies suggest the potential use of beta-adrenergic blocker in Covid-19

11. Beta-adrenergic blockers inhibit NOD-like receptor protein 3 (NLRP3) inflammasome

12. Use of beta-adrenergic blockers are safe in respiratory illness condition

NOD: nucleotide-binding oligomerization domain-like receptors.

Vasanthakumar N. Beta-adrenergic blockers as a potential treatment for Covid-19 patients. BioEssays. 2020;42:2000094.

 PubMed Web of Science ®Google Scholar